Mangoceuticals(Mgrx) Financials: Return On Equity Compared To Industry Average, Plus Other Key Ratios
Profitability Trend (Last 5 Years)
Profitability - return on equity
This chart shows the historical trend of return on equity for MGRX compared to its industry average over the recent years.
Ratio Definition and Interpretation
Name: Return on Equity (ROE)
Definition: ROE shows how much profit the company earns for its shareholders based on their invested equity. It’s one of the most watched profitability ratios. A consistently high ROE signals strong management and efficient use of shareholder capital. But artificially high ROE may sometimes be boosted by excessive debt.
Interpretation:
• In '2022', MGRX's return on equity was -669.0%, measuring profitability for shareholders. Industry average for Misc Health and Biotechnology Services in '2022' stood at -119.0%.
• In '2023', MGRX's return on equity was -1326.7%, measuring profitability for shareholders. The decline from '2022' may indicate some operational or financial challenges. Industry average for Misc Health and Biotechnology Services in '2023' stood at -5.7%. Industry average increased by 113.3% compared to previous year.
• In '2024', MGRX's return on equity was -118.3%, measuring profitability for shareholders. The increase since '2023' reflects strengthening financial performance. Industry average for Misc Health and Biotechnology Services in '2024' stood at -24.7%. Industry average declined by 19.0% from previous year.
Overall, MGRX's return on equity has been volatile but showed an upward trend over the past 3 years.
Formula: ROE = Net Income / Shareholders' Equity
Good Range: 10%-20% desirable for many industries.